Ayako Kawabata1, Nozomu Yanaihara2, Chie Nagata3, Misato Saito1, Daito Noguchi4, Masataka Takenaka1, Yasushi Iida1, Hirokuni Takano4, Kyosuke Yamada1, Masami Iwamoto5, Takako Kiyokawa5, Aikou Okamoto1. 1. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan. 2. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan. Electronic address: yanazou@jikei.ac.jp. 3. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan; Department of Education for Clinical Research, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. 4. Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa-shi, Chiba 277-0004, Japan. 5. Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan.
Abstract
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) frequently presents at an early stage. In stage I OCCC, the prognosis differs according to substage. In particular, predictive biomarkers and new treatment strategies are needed for stage IC2/IC3 disease. We investigated tumor biology and prognostic factors for stage I OCCC from a clinicopathological perspective, including the expression of ARID1A and IL-6, which are considered critical for OCCC carcinogenesis. METHODS: A retrospective cohort study of 192 patients with stage I OCCC treated at a single institution was performed. We calculated overall survival (OS) with respect to 12 clinicopathological parameters that included the unique and diverse histological features of OCCC. RESULTS: The estimated 5-year OS rate in patients with all stage I OCCC was 88.9% during a median of 91months of follow-up. The multivariate analysis indicated that substage classification and IL-6 expression status were associated with poor OS (p=0.010 and p=0.027, respectively). Loss of ARID1A expression had no impact on survival; however, it was associated with substage (p=0.001), capsule rupture status (p=0.011), and ascites cytology (p=0.016). No clear association was found between ARID1A and IL-6 expressions. Histological findings, including the presence of endometriosis, adenofibroma, architectural pattern, and tumor cell type, showed no prognostic effects. CONCLUSIONS: Both substage classification and IL-6 expression status may be independent prognostic factors in stage I OCCC. Therefore, IL-6 molecular stratification may be crucial in optimizing therapeutic strategies for early stage OCCC to improve survival.
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) frequently presents at an early stage. In stage I OCCC, the prognosis differs according to substage. In particular, predictive biomarkers and new treatment strategies are needed for stage IC2/IC3 disease. We investigated tumor biology and prognostic factors for stage I OCCC from a clinicopathological perspective, including the expression of ARID1A and IL-6, which are considered critical for OCCC carcinogenesis. METHODS: A retrospective cohort study of 192 patients with stage I OCCC treated at a single institution was performed. We calculated overall survival (OS) with respect to 12 clinicopathological parameters that included the unique and diverse histological features of OCCC. RESULTS: The estimated 5-year OS rate in patients with all stage I OCCC was 88.9% during a median of 91months of follow-up. The multivariate analysis indicated that substage classification and IL-6 expression status were associated with poor OS (p=0.010 and p=0.027, respectively). Loss of ARID1A expression had no impact on survival; however, it was associated with substage (p=0.001), capsule rupture status (p=0.011), and ascites cytology (p=0.016). No clear association was found between ARID1A and IL-6 expressions. Histological findings, including the presence of endometriosis, adenofibroma, architectural pattern, and tumor cell type, showed no prognostic effects. CONCLUSIONS: Both substage classification and IL-6 expression status may be independent prognostic factors in stage I OCCC. Therefore, IL-6 molecular stratification may be crucial in optimizing therapeutic strategies for early stage OCCC to improve survival.
Authors: Karolin Heinze; Tayyebeh M Nazeran; Sandra Lee; Pauline Krämer; Evan S Cairns; Derek S Chiu; Samuel Cy Leung; Eun Young Kang; Nicola S Meagher; Catherine J Kennedy; Jessica Boros; Friedrich Kommoss; Hans-Walter Vollert; Florian Heitz; Andreas du Bois; Philipp Harter; Marcel Grube; Bernhard Kraemer; Annette Staebler; Felix Kf Kommoss; Sabine Heublein; Hans-Peter Sinn; Naveena Singh; Angela Laslavic; Esther Elishaev; Alex Olawaiye; Kirsten Moysich; Francesmary Modugno; Raghwa Sharma; Alison H Brand; Paul R Harnett; Anna DeFazio; Renée T Fortner; Jan Lubinski; Marcin Lener; Aleksandra Tołoczko-Grabarek; Cezary Cybulski; Helena Gronwald; Jacek Gronwald; Penny Coulson; Mona A El-Bahrawy; Michael E Jones; Minouk J Schoemaker; Anthony J Swerdlow; Kylie L Gorringe; Ian Campbell; Linda Cook; Simon A Gayther; Michael E Carney; Yurii B Shvetsov; Brenda Y Hernandez; Lynne R Wilkens; Marc T Goodman; Constantina Mateoiu; Anna Linder; Karin Sundfeldt; Linda E Kelemen; Aleksandra Gentry-Maharaj; Martin Widschwendter; Usha Menon; Kelly L Bolton; Jennifer Alsop; Mitul Shah; Mercedes Jimenez-Linan; Paul Dp Pharoah; James D Brenton; Kara L Cushing-Haugen; Holly R Harris; Jennifer A Doherty; Blake Gilks; Prafull Ghatage; David G Huntsman; Gregg S Nelson; Anna V Tinker; Cheng-Han Lee; Ellen L Goode; Brad H Nelson; Susan J Ramus; Stefan Kommoss; Aline Talhouk; Martin Köbel; Michael S Anglesio Journal: J Pathol Date: 2022-02-07 Impact factor: 9.883
Authors: Eleftherios P Samartzis; S Intidhar Labidi-Galy; Michele Moschetta; Mario Uccello; Dimitrios R Kalaitzopoulos; J Alejandro Perez-Fidalgo; Stergios Boussios Journal: Ann Transl Med Date: 2020-12
Authors: Christine Mehner; Erin Miller; Alexandra Hockla; Mathew Coban; S John Weroha; Derek C Radisky; Evette S Radisky Journal: Oncogene Date: 2020-09-14 Impact factor: 9.867